Iberdomide, bortezomib, and dexamethasone (IberVd) in transplant-ineligible (TNE) newly diagnosed multiple myeloma (NDMM): Updated results from the CC-220-MM-001 trial
Por:
White, D, Lipe, B, Mesa, MG, Niesvizky, R, Oriol, A, Sureda, A, Bhutani, M, Rodriguez, CE, Khan, AM, Amatangelo, M, Jeyaraju, D, Jin, KX, Solomon, T, Hong, K, Amin, A, Aina, O, Maciag, P, van de Donk, NWCJ and Lonial, S
Publicada:
1 jun 2025
Resumen:
Filiaciones:
Dalhousie Univ, Halifax, NS, Canada
Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada
Univ Rochester, Med Ctr, Dept Med, Rochester, NY USA
Vall dHebron Hosp, Hematol Dept, Barcelona, Spain
Weill Cornell Med, Div Oncol & Hematol, New York, NY USA
Hosp Germans Trias i Pujol, Catalan Inst Oncol, Badalona, Spain
Hosp Germans Trias i Pujol, Josep Carreras Inst, Badalona, Spain
Univ Barcelona, Inst Catala Oncol LHospitalet L Barcelona, Barcelona, Spain
Wake Forest Univ, Dept Hematol Oncol & Blood Disorders, Div Plasma Cell Disorders, Atrium Hlth,Levine Canc Inst,Sch Med, Charlotte, NC USA
Hosp Gen Univ Gregorio Maranon, IiSGM, Madrid, Spain
Ohio State Univ, Comprehens Canc Ctr, James Canc Hosp, Columbus, OH USA
Ohio State Univ, Solove Res Inst, Comprehens Canc Ctr, Columbus, OH USA
Bristol Myers Squibb, Princeton, NJ USA
Univ Amsterdam, Vrije Univ Amsterdam, Med Ctr, Dept Hematol, Amsterdam, Netherlands
Canc Ctr Amsterdam, Amsterdam, Netherlands
Emory Univ Hosp, Winship Canc Inst, Atlanta, GA USA
|